LGI1 Antibody: FITC

The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist; this LGI1 antibody will recognize only the longer form.

ADLTE Antibody, ADPAEF Antibody, ADPEAF Antibody, Epitempin 1 Antibody, EPT Antibody, ETL1 Antibody, IB1099 Antibody, leucine rich glioma inactivated 1 Antibody, OTTHUMP00000020121 Antibody, OTTHUMP00000020122 Antibody

Fusion protein amino acids 37-113 (LRRNT domain and first LRR repeat) of mouse LGI1. Rat: 100% identity (77/77 amino acids identical). Human: 98% identity (76/77 amino acids identical). ~50% identity with LGI2, LGI3 and LGI4.

1 µg/ml of SMC-461 was sufficient for detection of LGI1 in 20 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.

1. Chernova O.B., Somerville R.P. and Cowell J.K. (1998) Oncogene. 17:2873-81. 2. Fialka F., et al. (2008) Oral Oncol. 3. Gu W., et al. (2005) Mol. Biol. Evol. 22:2209-16. 4. Fukata Y., et al. (2006) Science. 313:1792-5.